317 related articles for article (PubMed ID: 15461821)
1. The fallacy of enrolling only high-risk subjects in cancer prevention trials: is there a "free lunch"?
Baker SG; Kramer BS; Corle D
BMC Med Res Methodol; 2004 Oct; 4():24. PubMed ID: 15461821
[TBL] [Abstract][Full Text] [Related]
2. Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study.
Brunekreef B; Beelen R; Hoek G; Schouten L; Bausch-Goldbohm S; Fischer P; Armstrong B; Hughes E; Jerrett M; van den Brandt P
Res Rep Health Eff Inst; 2009 Mar; (139):5-71; discussion 73-89. PubMed ID: 19554969
[TBL] [Abstract][Full Text] [Related]
3. Seven ways to increase power without increasing N.
Hansen WB; Collins LM
NIDA Res Monogr; 1994; 142():184-95. PubMed ID: 9243537
[TBL] [Abstract][Full Text] [Related]
4. Use of the bootstrap in analysing cost data from cluster randomised trials: some simulation results.
Flynn TN; Peters TJ
BMC Health Serv Res; 2004 Nov; 4(1):33. PubMed ID: 15550169
[TBL] [Abstract][Full Text] [Related]
5. [Controlled randomized clinical trials].
Jaillon P
Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
[TBL] [Abstract][Full Text] [Related]
6. Multiplicity-adjusted sample size requirements: a strategy to maintain statistical power with Bonferroni adjustments.
Leon AC
J Clin Psychiatry; 2004 Nov; 65(11):1511-4. PubMed ID: 15554764
[TBL] [Abstract][Full Text] [Related]
7. Implementing a decision-theoretic design in clinical trials: why and how?
Palmer CR; Shahumyan H
Stat Med; 2007 Nov; 26(27):4939-57. PubMed ID: 17582801
[TBL] [Abstract][Full Text] [Related]
8. Evidence-based dermatology: number needed to treat and its relation to other risk measures.
Manriquez JJ; Villouta MF; Williams HC
J Am Acad Dermatol; 2007 Apr; 56(4):664-71. PubMed ID: 17367615
[TBL] [Abstract][Full Text] [Related]
9. Statistical aspects of fish vaccination trials.
Jarp J; Tverdal A
Dev Biol Stand; 1997; 90():311-20. PubMed ID: 9270859
[TBL] [Abstract][Full Text] [Related]
10. Parametric versus non-parametric statistics in the analysis of randomized trials with non-normally distributed data.
Vickers AJ
BMC Med Res Methodol; 2005 Nov; 5():35. PubMed ID: 16269081
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the statistical power of different methods for the analysis of cluster randomization trials with binary outcomes.
Austin PC
Stat Med; 2007 Aug; 26(19):3550-65. PubMed ID: 17238238
[TBL] [Abstract][Full Text] [Related]
12. Statistical consideration of the strategy for demonstrating clinical evidence of effectiveness--one larger vs two smaller pivotal studies.
Shun Z; Chi E; Durrleman S; Fisher L
Stat Med; 2005 Jun; 24(11):1619-37; discussion 1639-56. PubMed ID: 15568207
[TBL] [Abstract][Full Text] [Related]
13. Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisited.
Klein EA; Tangen CM; Goodman PJ; Lippman SM; Thompson IM
J Clin Oncol; 2005 Oct; 23(30):7460-6. PubMed ID: 16157937
[TBL] [Abstract][Full Text] [Related]
14. Robustness and power of analysis of covariance applied to ordinal scaled data as arising in randomized controlled trials.
Sullivan LM; D'Agostino RB
Stat Med; 2003 Apr; 22(8):1317-34. PubMed ID: 12687657
[TBL] [Abstract][Full Text] [Related]
15. Adaptive design and estimation in randomized clinical trials with correlated observations.
Yin G; Shen Y
Biometrics; 2005 Jun; 61(2):362-9. PubMed ID: 16011682
[TBL] [Abstract][Full Text] [Related]
16. A general approach for sample size and statistical power calculations assessing of interventions using a mixture model in the presence of detection limits.
Nie L; Chu H; Cole SR
Contemp Clin Trials; 2006 Oct; 27(5):483-91. PubMed ID: 16769254
[TBL] [Abstract][Full Text] [Related]
17. Availability of large-scale evidence on specific harms from systematic reviews of randomized trials.
Papanikolaou PN; Ioannidis JP
Am J Med; 2004 Oct; 117(8):582-9. PubMed ID: 15465507
[TBL] [Abstract][Full Text] [Related]
18. Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials.
Wijeysundera DN; Austin PC; Hux JE; Beattie WS; Laupacis A
J Clin Epidemiol; 2009 Jan; 62(1):13-21.e5. PubMed ID: 18947971
[TBL] [Abstract][Full Text] [Related]
19. How to deal with multiple treatment or dose groups in randomized clinical trials?
Hothorn LA
Fundam Clin Pharmacol; 2007 Apr; 21(2):137-54. PubMed ID: 17391286
[TBL] [Abstract][Full Text] [Related]
20. Optimal conditional error functions for the control of conditional power.
Brannath W; Bauer P
Biometrics; 2004 Sep; 60(3):715-23. PubMed ID: 15339294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
